Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study

INTRODUCTION: The 16-week randomised, placebo-controlled INCREASE trial (RCT) met its primary end-point by improving 6-min walk distance (6MWD) in patients receiving inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD). The open-label extension (OLE) evaluated lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Waxman, Aaron, Restrepo-Jaramillo, Ricardo, Thenappan, Thenappan, Engel, Peter, Bajwa, Abubakr, Ravichandran, Ashwin, Feldman, Jeremy, Hajari Case, Amy, Argula, Rahul G., Tapson, Victor, Smith, Peter, Deng, Chunqin, Shen, Eric, Nathan, Steven D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307984/
https://www.ncbi.nlm.nih.gov/pubmed/37080567
http://dx.doi.org/10.1183/13993003.02414-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307984/
https://www.ncbi.nlm.nih.gov/pubmed/37080567
http://dx.doi.org/10.1183/13993003.02414-2022

Ejemplares similares